UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025

1. Overview
The UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025 provides an in-depth review of the latest clinical advancements in lymphoma diagnosis and management. The course explores novel targeted therapies, cellular treatments like CAR T-cells and bispecifics, genomic testing, and multidisciplinary strategies for managing complex and relapsed lymphoma cases.
Course Date: 04/04/2025

The 22nd International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
The goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.
This event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.

2. Learning Objectives

At the conclusion of this educational activity, participants will be able to:

Assess clinical trial results of approved and investigational treatment strategies being studied in patients with indolent and aggressive subtypes of B-cell and T-cell non-Hodgkin lymphoma

Compare and contrast the selection and sequencing of therapeutic approaches for the care of patients with newly diagnosed and relapsed/refractory Hodgkin lymphoma

Evaluate the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL/SLL

Review approaches to the care of patients with rarer hematologic malignancies, including CNS lymphoma and Waldenstrom macroglobulinemia

Identify and nurture strategies to enhance communication and collaboration with the entire multidisciplinary healthcare team during the continuum of care of patients with lymphoma

3. Target Audience

Best for hematologists and oncologists who want updates on cellular therapies, genomic testing, and clinical management of complex lymphomas.

The target audience for this symposium is practicing oncologists, hematologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

4. Topics

01 Nivo-AVD for Advanced Stage Hodgkin Lymphoma

02 Bv-AVD for Advanced Stage Hodgkin Lymphoma

03 Contributions of the European Regimens to the Management of cHL

04 The Impact of 1L Therapy Selection on Subsequent HL Treatment Approaches

05 Prioritizing Clinical Research in Oncology Clinical Practice

06 Comparison of CAR T-Cell Therapies in RR Follicular Lymphoma

07 Comparison of Bispecific Therapies in RR Follicular Lymphoma

08 Non-T-Cell Engaging Treatment Options in RR Follicular Lymphoma

09 How I Approach Treatment-Naive CLL SLL

10 Challenges in Treating Patients with TP53-Mutated MCL

11 Role of Transplant and Cellular Therapy in RR MCL

12 Globalizing Lymphoma Research – Challenges and Opportunities

13 Current Role of BTK Inhibitors in Frontline MCL

14 Overview of Treatment Options and Key Trials for CNS Lymphoma

15 A Ticking Time B-Cell Lymphoma – A Case on High-Risk DLBCL for CNS Relapse

16 Challenging Case Discussion – Newly Diagnosed Low-Grade FL Transformed Into Double-hit DLBCL With Secondary CNS Lymph…

17 Frontline Treatment Options in Newly Diagnosed DLBCL

18 RR DLBCL – The Role of CAR T-Cells vs. Bispecifics in First Relapse

19 FrailOlder Patients With DLBCL – A Persistent Challenge

20 Baseline Genomic Testing in Lymphoma – Are We There Yet

21 Next Generation Hematopathology and the Standard of Care in Lymphoma

22 Mediastinal Gray Zone Lymphoma Case-Based Panel Discussion – Diagnostic Criteria & Management Approach

23 Novel Therapies for Lymphoma – Focus on CELMoDs and BTK Degraders

24 Novel T-Cell Engaging Therapy Approaches – How Close are They to Prime Time

25 Improving HRQoL for Patients With Lymphoma

26 Nursing Perspective on Managing Neurotoxicity – What Tools Do We Have

27 Incorporating Patient-Reported Outcomes in Clinical Trials